



17 July 2025

Our Ref: FOI 1270

Dear

**Freedom of Information Act 2000
Information in relation to Endometrial Cancer**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 4 July 2025.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care and Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

A1. No, the Trust does not provide Systemic Anti-Cancer Therapy (SACT) treatments for Endometrial Cancer. Patients are referred to the Belfast Health & Social Care Trust for treatment.

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- **Dostarlimab (Jemperli)**
- **Dostarlimab (Jemperli) AND Chemotherapy**
- **Hormone therapy (Progesterone or Letrozole)**
- **Pembrolizumab (Keytruda) monotherapy**
- **Lenvatinib + Pembrolizumab (Lenvima +Keytruda)**
- **Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)**
- **Any other SACT**
- **Any other Chemotherapy**
- **Durvalumab with platinum-based chemotherapy**
- **Pembrolizumab with platinum-based chemotherapy**

A2. N/A.

Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

A3. N/A.